Education
About Us
Working with TipRanks
Follow Us
Seres Therapeutics Inc. (DE:1S90)
:1S90
Earnings Data
Report Date
Mar 10, 2026Before Open (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
-1.75Last Year’s EPS
-1.56Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call highlighted significant clinical progress and financial recovery, supported by external funding and strategic cost reductions. However, the dependency on securing further capital for future studies poses a notable challenge.Company Guidance
SER-155 Clinical Progress
SER-155 Phase Ib study showed a 77% relative risk reduction in bacterial bloodstream infections, decreased antibiotic exposure, and febrile neutropenia. The FDA provided constructive feedback, aligning on key study parameters for the Phase II protocol.
Non-Dilutive Funding and Recognition
Seres received a $3.6 million award from CARB-X to develop an oral liquid formulation of SER-155, highlighting global recognition of the potential of their biotherapeutic approach to address antimicrobial resistance.
Financial Turnaround
Seres reported a net income from continuing operations of $8.2 million in Q3 2025, compared to a net loss of $51 million in Q3 2024, with a $27.2 million gain on the sale of VOWST.
Cost Reduction Measures
Implemented a 25% workforce reduction to extend cash runway and focus resources on core development priorities.
DE:1S90 Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
DE:1S90 Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Nov 05, 2025 | €12.82 | €11.30 | -11.86% |
Aug 06, 2025 | €12.44 | €11.88 | -4.50% |
May 07, 2025 | €0.20 | €0.20 | 0.00% |
Mar 13, 2025 | €13.46 | €11.84 | -12.00% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Seres Therapeutics Inc. (DE:1S90) report earnings?
Seres Therapeutics Inc. (DE:1S90) is schdueled to report earning on Mar 10, 2026, Before Open (Confirmed).
What is Seres Therapeutics Inc. (DE:1S90) earnings time?
Seres Therapeutics Inc. (DE:1S90) earnings time is at Mar 10, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Seres Therapeutics Inc. stock?
The P/E ratio of Seres Therapeutics is N/A.
What is DE:1S90 EPS forecast?
DE:1S90 EPS forecast for the fiscal quarter 2025 (Q4) is -1.75.